KAS
CLDX icon

Kemnay Advisory Services’s Celldex Therapeutics CLDX Stock Holding History

Kemnay Advisory Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5K Buy
711
+160
+29% +$5.17K ﹤0.01% 573
2026
Q1 		$17.5K Buy
+551
New +$15K ﹤0.01% 766

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kemnay Advisory Services's CLDX Position: Q2 2026 in Review

Kemnay Advisory Services increased its Celldex Therapeutics (CLDX) stake by 29% in Q2 2026, buying an estimated $5.17K and bringing the position to 711 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #573.

Kemnay Advisory Services first reported a position in CLDX in Q1 2026 and has held it in 2 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Kemnay Advisory Services held 711 shares of Celldex Therapeutics worth $26.5K as of Q2 2026.
  • Kemnay Advisory Services bought 160 Celldex Therapeutics shares in Q2 2026, an estimated $5.17K.
  • Celldex Therapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #573 holding.
  • Kemnay Advisory Services first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.